Evidence map›Paper›PMID 33042157›Full record

ArticleFrontiers in immunology2020

Mast Cells in Alveolar Septa of COVID-19 Patients: A Pathogenic Pathway That May Link Interstitial Edema to Immunothrombosis.

Jarbas da Silva Motta Junior, Anna Flavia Ribeiro Dos Santos Miggiolaro, Seigo Nagashima, Caroline Busatta Vaz de Paula, Cristina Pellegrino Baena, Julio Scharfstein, Lucia de Noronha

Open access · goldAbstract readComparative Study
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 1 pooled it
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 1 synthesis or guideline pooled it, 106 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Bronchial Asthma and COVID-19: Etiology, Pathological Triggers, and Therapeutic Considerations.Pathophysiology : the official journal of the International Society for Pathophysiology · 2024
    Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Jarbas da Silva Motta JuniorSchool of Medicine, Pontifícia Universidade Católica do Paraná PUCPR, Curitiba, Brazil.
Anna Flavia Ribeiro Dos Santos MiggiolaroSchool of Medicine, Pontifícia Universidade Católica do Paraná PUCPR, Curitiba, Brazil.
Seigo NagashimaSchool of Medicine, Pontifícia Universidade Católica do Paraná PUCPR, Curitiba, Brazil.
Caroline Busatta Vaz de PaulaSchool of Medicine, Pontifícia Universidade Católica do Paraná PUCPR, Curitiba, Brazil.
Cristina Pellegrino BaenaSchool of Medicine, Pontifícia Universidade Católica do Paraná PUCPR, Curitiba, Brazil.
Julio ScharfsteinInstituto de Biofísica Carlos Chagas Filho, Universidade Federal Do Rio de Janeiro, Rio de Janeiro, Brazil.
Lucia de NoronhaSchool of Medicine, Pontifícia Universidade Católica do Paraná PUCPR, Curitiba, Brazil.
Pontifícia Universidade Católica do Paraná · BRHospital Santa Marcelina · BRUniversidade Federal do Rio de Janeiro · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is currently believed that innate immunity is unable to prevent the spread of SARS-CoV-2 from the upper airways to the alveoli of high-risk groups of patients. SARS-CoV-2 replication in ACE-2-expressing pneumocytes can drive the diffuse alveolar injury through the cytokine storm and immunothrombosis by upregulating the transcription of chemokine/cytokines, unlike several other respiratory viruses. Here we report histopathology data obtained in post-mortem lung biopsies of COVID-19, showing the increased density of perivascular and septal mast cells (MCs) and IL-4-expressing cells (

Indexed as

AdultAgedAged, 80 and overBetacoronavirusCoronavirus InfectionsCOVID-19FemaleHumansInfluenza A Virus, H1N1 SubtypeInfluenza, HumanInterleukin-4MaleMast CellsMiddle AgedPandemicsPneumonia, ViralIL4 protein, humanInterleukin-4KIT protein, humanProto-Oncogene Proteins c-kitcell-mediated immunityCOVID 19immune responsesinterleukin-4 (IL-4)mast cells (MC)SARS-CoV-2

Identifiers

PMID33042157
PMCPMC7530169
OpenAlexW3087093860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.